|Awarded On||February 21, 2019|
|Title||Deciphering the Underlying Biology and Translational Relevance of PD-L2|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Michael Curran|
|Cancer Sites||All Sites|
Unfortunately, as they form, cancers evolve means to hide from and locally dampen the immune system allowing them to thrive when they would otherwise be eliminated. A critical mechanism of cancer immune suppression is engagement of “immune checkpoint” receptors on T cells, the killer cells of the immune system necessary to eliminate cancer, by checkpoint ligands expressed by the tumor or its stroma. Antibodies which block these immune checkpoint receptors in the clinic can induce tumor regressions and even durable cures by denying tumors the capacity to inactivate the immune system. Blockade of one of these “immune checkpoint receptors”, PD-1, or its best-described ligand, PD-L1, has show...